Transplantation
Conference Coverage
Outcomes appear similar with MAC and RIC
SALT LAKE CITY—New research suggests outcomes may be similar whether patients receive myeloablative conditioning (MAC) or reduced-intensity...
News
Agent can reveal HSC engraftment faster
An imaging agent can safely show engraftment of hematopoietic stem cells (HSCs) just days after transplant, according to research published in The...
Conference Coverage
HSCT approach provides ‘excellent’ survival in FA
SALT LAKE CITY—A “risk-adjusted” approach leads to “excellent” survival in patients with Fanconi anemia (FA) undergoing alternative donor...
Conference Coverage
Study confirms higher risk of infection with CB transplant
SALT LAKE CITY—Results of a large, retrospective analysis support the notion that patients who receive cord blood (CB) transplants have a higher...
Conference Coverage
Team identifies biomarkers for cGVHD in kids
SALT LAKE CITY—Researchers say they have identified prognostic biomarkers for chronic graft-vs-host disease (cGVHD) in children. The group found...
Conference Coverage
Expanded UCB product can stand alone
SALT LAKE CITY—The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the...
Conference Coverage
Minihaplo-BMT can cure severe hemoglobinopathies
SALT LAKE CITY—Cure of severe hemoglobinopathies is now possible for most patients, according to a speaker at the 2018 BMT Tandem Meetings....
Conference Coverage
Regimen deemed ‘safe and feasible’ in MM
SALT LAKE CITY—A novel transplant regimen is “safe and feasible” for patients with multiple myeloma (MM), according to a presentation at the 2018...
News
Cognitive impairment in HSCT recipients
New research suggests the risk of cognitive impairment after hematopoietic stem cell transplant (HSCT) is greatest among recipients of...
News
JAK2 inhibition could reduce risk of GVHD
Preclinical research suggests that targeting JAK2 can reduce the risk of graft-versus-host disease (GVHD) in transplant recipients. Researchers...
News
Agent can decrease GI toxicity in MM patients
Results of a case-control study suggest a cytoprotective agent can reduce treatment-related gastrointestinal (GI) toxicity in patients with...